Free tool
Diagnostics stocks
We cover 25 companies grouped under the Diagnostics theme. The median market value in the group is $3.55B. Across the group, the median move over the past trading day is −0.06%. 68% of the 25 with a 200-day average trade above it. Price change over the past year runs from −86.1% to +141.9% across the middle 80 percent of the group, with a median of −6.7%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
25 of 150 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| NTRA | Natera, Inc. | $48.53B | Large cap | +107.59% | Nov 5, 2026 |
| LH | Labcorp Holdings Inc. | $27.39B | Large cap | +21.14% | Nov 3, 2026 |
| DGX | Quest Diagnostics Incorporated | $26.99B | Large cap | +38.12% | Oct 20, 2026 |
| GH | Guardant Health, Inc. | $22.94B | Large cap | +169.17% | Oct 28, 2026 |
| TEM | Tempus AI, Inc. | $12.40B | Large cap | −6.49% | Nov 3, 2026 |
| QGEN | Qiagen N.V. | $9.01B | Mid cap | −9.65% | Nov 4, 2026 |
| QIA.DE | Qiagen N.V. | $8.99B | Mid cap | −6.73% | Nov 4, 2026 |
| CAI | Caris Life Sciences, Inc. | $7.58B | Mid cap | −29.83% | Nov 4, 2026 |
| 6869.T | Sysmex Corporation | $7.28B | Mid cap | +3.66% | Nov 4, 2026 |
| BLLN | BillionToOne, Inc. | $4.54B | Mid cap | −11.68% | Nov 5, 2026 |
| ADPT | Adaptive Biotechnologies Corporation | $4.18B | Mid cap | +101.70% | Nov 4, 2026 |
| VCYT | Veracyte, Inc. Common Stock | $3.56B | Mid cap | +54.81% | Nov 3, 2026 |
| GRAL | GRAIL, Inc. | $3.55B | Mid cap | +136.66% | Nov 11, 2026 |
| WGS | GeneDx Holdings Corp. | $2.69B | Mid cap | −30.11% | Oct 27, 2026 |
| CDNA | CareDx, Inc. | $2.64B | Mid cap | +283.45% | Nov 3, 2026 |
| NEOG | Neogen Corporation | $2.54B | Mid cap | +103.83% | Oct 8, 2026 |
| NEO | NeoGenomics, Inc. | $2.26B | Mid cap | +145.34% | Oct 27, 2026 |
| ALIF-B.ST | AddLife AB (publ) | $2.08B | Mid cap | −7.20% | Oct 21, 2026 |
| SERA | Sera Prognostics, Inc. | $82.45M | Micro cap | −26.41% | Nov 16, 2026 |
| MDXH | MDxHealth SA | $72.15M | Micro cap | −84.51% | Nov 12, 2026 |
| PAVM | PAVmed Inc. | $42.54M | Micro cap | −63.21% | Nov 12, 2026 |
| CODX | Co-Diagnostics, Inc. | $8.73M | Micro cap | −87.22% | Nov 16, 2026 |
| CDIO | Cardio Diagnostics Holdings, Inc. | $5.71M | Micro cap | −48.46% | Nov 6, 2026 |
| VNRX | VolitionRx Limited | $4.89M | Micro cap | −97.47% | Nov 12, 2026 |
| REVB | Revelation Biosciences, Inc. | $3.80M | Micro cap | −91.25% | Nov 5, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.